Sorrento Therapeutics Completes Enrollment of Phase 2 Clinical Trial of Resiniferatoxin (RTX) for Treatment of Knee Pain in Moderate to Severe Osteoarthritis of the Knee (OAK) Patients
September 26, 2022 09:00 ET
|
Sorrento Therapeutics, Inc.
Phase 2 trial of RTX for OAK pain completed enrollment with last patient (n=120) dosedNo limiting toxicities have been encountered during the trial to date. Patients are now being monitored for...
RAYTHEON ALERT: Bragar Eagel & Squire, P.C. is Investigating Raytheon Technologies Corporation on Behalf of Long-Term Stockholders and Encourages Investors to Contact the Firm
December 17, 2021 21:00 ET
|
Bragar Eagel & Squire
NEW YORK, Dec. 17, 2021 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, is investigating potential claims against Raytheon Technologies...
FDA Clears Sorrento Phase 2 Trial Of Non-Opioid Product Candidate Resiniferatoxin (RTX) For Treatment of the Knee Pain in Osteoarthritis (OA) Patients
July 06, 2021 14:34 ET
|
Sorrento Therapeutics, Inc.
Phase 2 trial of RTX for OA pain to proceed following FDA clearance.Phase 1b data demonstrated RTX safety for a single intra-articular administration without dose limiting toxicity (DLT) at any doses...
Bragar Eagel & Squire is Investigating Certain Officers and Directors of Sequential Brands and Raytheon on Behalf of Long-Term Stockholders and Encourages Investors to Contact the Firm
January 22, 2021 20:00 ET
|
Bragar Eagel & Squire
NEW YORK, Jan. 22, 2021 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, is investigating certain officers and directors of Sequential Brands...
FINAL DEADLINE TUESDAY: ROSEN, RECOGNIZED INVESTOR COUNSEL, Reminds Raytheon Technologies Corporation f/k/a Raytheon Company Investors of Important December 29 Deadline in Securities Class Action; Encourages Investors with Losses in Excess of $100K to Contact the Firm – RTX, RTN
December 24, 2020 16:12 ET
|
The Rosen Law Firm PA
NEW YORK, Dec. 24, 2020 (GLOBE NEWSWIRE) -- Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Raytheon Technologies Corporation f/k/a Raytheon Company (NYSE:...
ROSEN, TRUSTED INVESTOR COUNSEL, Reminds Raytheon Technologies Corporation f/k/a Raytheon Company Investors of Important Deadline in Securities Class Action First Filed by the Firm; Encourages Investors with Losses in Excess of $100K to Contact Firm – RTX, RTN
December 15, 2020 16:08 ET
|
The Rosen Law Firm PA
NEW YORK, Dec. 15, 2020 (GLOBE NEWSWIRE) -- Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Raytheon Technologies Corporation f/k/a Raytheon Company (NYSE:...
ROSEN, A TOP RANKED FIRM, Reminds Raytheon Technologies Corporation f/k/a Raytheon Company Investors of Important December 29 Deadline in First Filed Securities Class Action Commenced by the Firm; Encourages Investors with Losses in Excess of $100K to Contact the Firm – RTX, RTN
December 04, 2020 16:30 ET
|
The Rosen Law Firm PA
NEW YORK, Dec. 04, 2020 (GLOBE NEWSWIRE) -- Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Raytheon Technologies Corporation f/k/a Raytheon Company (NYSE:...
ROSEN, TRUSTED INVESTOR COUNSEL, Announces Investigation of Securities Claims Against Raytheon Technologies Corporation – RTX, RTN
October 29, 2020 20:17 ET
|
The Rosen Law Firm PA
NEW YORK, Oct. 29, 2020 (GLOBE NEWSWIRE) -- Rosen Law Firm, a global investor rights law firm, announces it is investigating potential securities claims on behalf of shareholders of Raytheon...
Sorrento Releases Positive Results of Phase 1B Trial of Resiniferatoxin (RTX) In Reduction of OsteoArthritis (OA) Knee Pain
September 28, 2020 09:00 ET
|
Sorrento Therapeutics, Inc.
Phase 1b safety data at 6 month post-administration and Day 84 efficacy data available for all patients enrolled.No dose limiting toxicities at any of the doses tested (up to 30 ug) at 6 months...
Sorrento Therapeutics Presents Interim Positive Results of Phase 1b Resiniferatoxin (RTX) in Cancer Pain Trial
February 27, 2020 15:30 ET
|
Sorrento Therapeutics, Inc.
Fourteen subjects with advanced cancer pain received epidural RTX (04 to 15 ug)Most common treatment-related adverse event was transient post-procedure related painThree subjects at the higher doses...